Tryptamine compounds, and methods of cerebrovascular treatment therewith
申请人:Beecham-Wuelfing GmbH & Co. KG
公开号:US04980368A1
公开(公告)日:1990-12-25
A compound of formula (I) or a pharmaceutically acceptable salt thereof: ##STR1## wherein: R.sub.1 is hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy or halogen; R.sub.2 and R.sub.3 are both hydrogen or together represent a bond; R.sub.4 is selected from C.sub.1-6 alkyl, phenyl, phenyl C.sub.1-4 alkyl, COR.sub.8 where R.sub.8 is hydroxy, C.sub.1-6 alkoxy or NR.sub.9 R.sub.10 where R.sub.9 and R.sub.10 are independently hydrogen or C.sub.1-4 alkyl and CH.sub.2 OR.sub.11 and R.sub.11 is hydrogen, C.sub.1-4 alkyl or C.sub.1-4 alkanoyl; R.sub.5 is hydrogen, C.sub.1-6 alkyl or phenyl C.sub.1-4 alkyl; R.sub.6 is phenyl C.sub.1-7 alkyl in which the phenyl moiety is optionally substituted by one or two of halogen, ortho-nitro, meta- or para-methoxy, methyl or NR.sub.12 R.sub.13 wherein R.sub.12 and R.sub.13 are independently hydrogen or C.sub.1-6 alkyl or R.sub.12 and R.sub.13 together are C.sub.2-6 polymethylene or the phenyl moiety is 3,4-disubstituted by methylenedioxy or ethylenedioxy; and R.sub.7 is hydrogen or C.sub.1-4 alkyl, processes for its preparation and its use as a pharmaceutical.
3-(2-Aminoethyl)indole and -indoline derivatives, processes for their preparation and pharmaceutical compositions containing them
申请人:SMITHKLINE BEECHAM PHARMA GmbH
公开号:EP0233413A2
公开(公告)日:1987-08-26
A compound of formula (1) or a pharmaceutically acceptable salt thereof:
wherein:
R, is hydrogen, C1-6 alkyl, C1-6 alkoxy or halogen;
R2 and R3 are both hydrogen or together represent a bond;
R4 is selected from C1-6 alkyl, phenyl, phenyl-C1-4 alkyl, CORe where R8 is hydroxy, C1-6 alkoxy or NR9R10 where R9 and R10 are independently hydrogen or C1-4 alkyl and CH2OR11 where R11 is hydrogen, C1-4 alkyl or C1-4 alkanoyl;
R6 is hydrogen, C1-6 alkyl or phenyl C1-4 alkyl;
R6 is phenyl C1-7 alkyl in which the phenyl moiety is optionally substituted by one or two of halogen, ortho-nitro. meta-or para-methoxy, methyl or NR12R13 wherein R12 and R13
are independently hydrogen or C1-6 alkyl or R12 and R13 together are C2-6 polymethylene or the phenyl moiety is 3,4- disubstituted by methylenedioxy or ethylenedioxy; and
R7 is hydrogen or C1-4 alkyl, processes for its preparation and its use as a pharmaceutical.